The Oncology Institute Appoints New CIO and CPO to Enhance Leadership in Value-Based Cancer Care

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Jan 09 2026

0mins

TOI+6.53%

Should l Buy TOI?

Source: Newsfilter

Leadership Changes: The Oncology Institute has appointed Rakesh Panda as Chief Information Officer, leveraging over 25 years of IT and digital transformation experience to advance the company's technology strategy, particularly in AI and data privacy, aimed at enhancing value-based cancer care.
HR Strengthening: Nolan Mariano has been appointed Chief People Officer, overseeing HR operations and talent acquisition, and with 18 years of industry experience, he will enhance company culture and employee development to support the rapid growth of The Oncology Institute.
Technology-Driven Care Platform: The new CIO will focus on the technology-enabled care delivery platform, driving innovations to improve patient experience and care quality, thereby strengthening the company's competitive position in the cancer care market.
Sustained Growth Strategy: CEO Daniel Virnich emphasized the promotion of internal leaders, indicating the company's commitment to providing world-class community-based cancer care while continuing to experience rapid growth, further solidifying its leadership position in the industry.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy TOI?" and start using high-conviction signals backed by rigorous historical data.

TOI

$2.61+Infinity%1D

Analyst Views on TOI

Wall Street analysts forecast TOI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TOI is 6.67 USD with a low forecast of 5.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Analyst Rating

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 2.450

Low

5.00

Averages

6.67

High

8.00

Current: 2.450

Low

5.00

Averages

6.67

High

8.00

Needham

Buy

initiated

2025-11-25

Reason

Needham

Price Target

AI Analysis

2025-11-25

initiated

Buy

Reason

Needham initiated coverage of Oncology Institute with a Buy rating and $5 price target. As value-based care adoption accelerates, Oncology Institute appears well positioned to help curb rising oncology costs, with early relationships typically starting in fee-for-service and expanding into downside risk, the analyst tells investors in a research note. Demand supports a durable 20%+ growth outlook, a shift toward VBC could lift EBITDA margins into the mid-single digits, and shares look undervalued ahead of expected positive EBITDA in Q4 and FY26, the firm says.

Needham

Matthew Shea

initiated

2025-11-25

Reason

Needham

Matthew Shea

Price Target

2025-11-25

initiated

Reason

Needham analyst Matthew Shea initiated coverage of Oncology Institute with a Buy rating and $5 price target. The need for solutions that can mitigate oncology cost trends "could not be more apparent," says the analyst, who views Oncology Institute as "a critical player in addressing this gap." The firm sees demand seeding durable 20%-plus topline growth and sees an opportunity for EBITDA margins to scale towards mid-single digits over the medium term as mix shifts towards value-based care, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TOI

Unlock Now

About TOI

The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to over 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

M33 Growth Partners with US Neurology Associates to Transform Neurology Care

Jan 09 2026Globenewswire

Strategic Partnership: M33 Growth partners with US Neurology Associates to enhance the quality of neurology care by integrating resources and infrastructure to meet the growing patient demand.
Leadership Team: Nitin Jain as CEO and Brad Hively as Chairman bring extensive management experience in healthcare, which will drive the company's growth.
Innovative Care Platform: USNA will deliver comprehensive care including in-office infusions, diagnostics, and clinical trials, aiming to improve patient experience and reduce care costs through a one-stop service.
Value-Oriented Approach: USNA is committed to collaborating with payers to promote value-based care models, aiming to provide efficient and cost-effective neurology solutions through integrated community clinics.